Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Total Liabilities
Everything the company owes to creditors and other parties.
Pelthos Therapeutics Inc.AMEX: PTHS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 2059.3% from a year ago
Total liabilities stood at $110.28M at the end of Q1 FY2026, up 2059.3% from a year earlier and up 20.5% from the prior quarter. Over 3 fiscal years it compounded at +189.8% a year.
Context
- Total liabilities amounted to 75.9% of total assets at the end of Q1 FY2026, down 484.6 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +2059.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 91.52M USD
- Year-over-year change
- +2141.3%
- 3-year CAGR
- +189.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.52M | +2141.3% |
| FY2024 | 2024-12-31 | 4.08M | -37.6% |
| FY2023 | 2023-12-31 | 6.54M | +73.9% |
| FY2022 | 2022-12-31 | 3.76M | — |
Total Liabilities vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 total liabilities of $110.28M is the 2nd highest of the 4 companies compared; the peer median is $12M.
- Its year-over-year change of +2059.3% is the 2nd highest of 4, against a peer median of +375.0%.
- Total liabilities amounts to 75.9% of total assets for PTHS, versus a peer median of 16.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $392.05M | +9466.9% | +231.1% | 16.8% | |
| Mar 2026 | $110.28M | +2059.3% | +189.8% | 75.9% | |
| Mar 2026 | $12M | +83.5% | +18.6% | 38.9% | |
| Mar 2026 | $1.69M | +375.0% | +64.8% | 15.5% | |
| Peer median (excluding PTHS) | $12M | +375.0% | +64.8% | 16.8% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.